UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2024 P 1197-9
Program Prior Authorization/Notification
Medication Epclusa® (sofosbuvir/velpatasvir)
P&T Approval Date 8/2016, 8/2017, 8/2018, 8/2019, 8/2020, 8/2021, 8/2022, 8/2023,
8/2024
Effective Date 11/1/2024
1. Background:
Epclusa (sofosbuvir/velpatasvir) is a fixed-dose combination of sofosbuvir, a hepatitis C virus
(HCV) nucleotide analog NS5B polymerase inhibitor, and velpatasvir, an HCV NS5A
inhibitor, and is indicated for the treatment of adults and pediatric patients 3 years of age and
older with chronic HCV genotype 1, 2, 3, 4, 5 or 6 infection:
• without cirrhosis or with compensated cirrhosis
• with decompensated cirrhosis for use in combination with ribavirin
2. Coverage Criteriaa:
A. For the treatment of chronic hepatitis C genotype 1, 2, 3, 4, 5 or 6 infection, Epclusa will be
approved based on all of the following criteria:
1. Diagnosis of chronic hepatitis C genotype 1, 2, 3, 4, 5 or 6 infection
-AND-
2. Patient is not receiving Epclusa in combination with another HCV direct acting antiviral
agent [e.g., Sovaldi (sofosbuvir)]
-AND-
3. One of the following:
a. Patient does not have decompensated liver disease (e.g., Child-Pugh Class B or C)
-OR-
b. Both of the following:
(1) Patient has decompensated liver disease (e.g., Child-Pugh Class B or C)
-AND-
(2) Used in combination with ribavirin
Authorization will be issued for 12 weeks.
© 2024 UnitedHealthcare Services Inc.
1
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
3. Additional Clinical Rules
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-
10) and/or claim logic. Use of automated approval and re-approval processes varies by
program and/or therapeutic class.
• Supply limits may be in place
• Medical necessity may be in place.
4. References:
1. Epclusa [package insert]. Foster City, CA: Gilead Sciences, Inc.; April 2022.
Program Prior Authorization/Notification – Epclusa (sofosbuvir/velpatasvir)
Change Control
Date Change
8/2016 New program.
8/2017 Annual review with no changes to coverage criteria. Updated
reference.
8/2018 Annual review with no changes to coverage criteria. Updated
reference.
8/2019 Annual review with no changes to coverage criteria.
8/2020 Annual review with no changes to coverage criteria. Updated
reference.
8/2021 Annual review. Updated background with no changes to clinical
criteria. Updated reference.
8/2022 Annual review. Added Child-Pugh classes for decompensated cirrhosis.
8/2023 Annual review with no changes to coverage criteria. Updated
reference.
8/2024 Annual review with no changes to coverage criteria.
© 2024 UnitedHealthcare Services Inc.
2